ATLANTA, Nov. 1 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. , a biopharmaceutical company dedicated to the development of innovative gene transfer therapy products for the treatment of severe cardiovascular and peripheral vascular disease, announced that Richard Otto, president and chief executive officer, will be presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8, 2005 at 9:05 a.m. EST at the New York Palace Hotel in New York City.
Mr. Otto will discuss Corautus’ GENASIS Phase IIb clinical trial for severe cardiovascular disease, present the Company’s technology platform, and review additional clinical development activities and the Company’s overall business strategy. The presentation will be accessible by webcast from the Investor Relations section of Corautus’ website or by accessing the following link: http://wsw.com/webcast/rrshq7/caq/ .
Corautus Genetics Inc. is a clinical-stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus is currently developing and testing a gene transfer product using the Vascular Endothelial Growth Factor-2 (VEGF-2) gene to promote therapeutic angiogenesis in ischemic muscle. In the Fall of 2004, Corautus commenced the GENASIS Trial, a Phase IIb clinical trial to evaluate the safety and efficacy of VEGF-2 for the treatment of severe cardiovascular disease. The GENASIS clinical trial is a randomized, double-blind, dose-ranging and placebo- controlled trial that will enroll up to 404 patients with Class III or IV angina in approximately 33 cardiac medical centers in the United States. Angina results from coronary artery disease and manifests as chest pain due to a lack of adequate oxygen supply to the heart muscle. The GENASIS trial will evaluate the efficacy and safety of defined doses of VEGF-2 delivered percutaneously via the Boston Scientific Corporation Stiletto(TM) endocardial direct injection catheter system.
For more information, please visit http://www.corautus.com . Company Contact: Michael K. Steele Vice President - Business Development (404) 526-6212 msteele@corautus.com Investor Relations Contacts: Lippert/Heilshorn & Assoc Kim Sutton Golodetz Kgolodetz@lhai.com Anne Marie Fields afields@lhai.com 212-838-3777
Corautus Genetics Inc.
CONTACT: Michael K. Steele, Vice President - Business Development ofCorautus Genetics Inc., +1-404-526-6212, or msteele@corautus.com ; orInvestor Relations, Kim Sutton Golodetz, Kgolodetz@lhai.com , or Anne MarieFields, afields@lhai.com , both of Lippert-Heilshorn & Assoc,+1-212-838-3777
